> Markdown version of https://haygoodhealth.com/c/anticoagulation for AI agents. You are welcome here, and welcome back anytime. What an agent can do: https://haygoodhealth.com/agents .

# Anticoagulation (blood thinners) - Haygood Health

A knowledge clinic for families

[Haygood Health](/)

[← Haygood Health](/)

### [Anticoagulation (blood thinners)](/c/anticoagulation)

MechanismESTABLISHEDOutcomeB (therapeutic dosing; stopping never tested)

Claimed

Therapeutic blood thinners reduce clots and death in hospitalized COVID-19 patients, and stopping them causes harm.

What holds up

Heparin preventing and treating thrombosis is textbook pharmacology, and COVID-19's prothrombotic state (endothelial injury, immunothrombosis) was demonstrated in autopsy and cohort studies across many centers. In 2,219 non-critically ill patients, therapeutic heparin raised the probability of more organ support-free days (adjusted OR 1.27) and added 4.0 percentage points of survival to discharge without organ support, at a bleeding cost of 1.9% vs 0.9% major bleeding. HEP-COVID (257 high D-dimer patients) cut the 30-day composite of thromboembolism or death in non-ICU patients. Period guidelines recommend therapeutic heparin for non-critically ill inpatients and advise switching chronic oral anticoagulants to shorter-acting injectable agents on admission when deterioration, renal change, or procedures are a concern.

What it does not show

The large multiplatform RCT showed a real outcome signal in non-critically ill patients and HEP-COVID confirmed it in high-risk non-ICU patients, but the critically ill arm was stopped for futility and the ACTION trial contradicted the benefit, so this is not a uniformly replicated mortality win. In critically ill patients the same strategy was stopped for futility (99.9% posterior probability; survival to discharge 62.7% vs 64.5%), and INSPIRATION showed intermediate-dose escalation in the ICU was no better than standard prophylaxis (45.7% vs 44.1%) while adding severe thrombocytopenia cases. The ACTION trial showed no clinical benefit and more bleeding. The mortality signal is composite-driven, not a clean standalone death reduction. On stopping them: There is no direct human outcome evidence that discontinuation itself causes excess clots or death in this population; the claim as stated overreaches what was tested, and a discontinuation RCT does not exist to settle it.

Evidence for

ATTACC/ACTIV-4a/REMAP-CAP Investigators (Lawler PR et al.), N Engl J Med 2021;385(9):790-802, PMID 34351721, REMAP-CAP/ACTIV-4a/ATTACC Investigators (Goligher EC et al.), N Engl J Med 2021;385(9):777-789, PMID 34351722, INSPIRATION Investigators (Sadeghipour P et al.), JAMA 2021;325(16):1620-1630, PMID 33734299, Barnes GD et al. (Anticoagulation Forum guidance), J Thromb Thrombolysis 2020, PMID 32440883, Spyropoulos AC et al., JAMA Intern Med 2021;181(12):1612-1620, DOI 10.1001/jamainternmed.2021.6203

Sources

VERIFIED ATTACC/ACTIV-4a/REMAP-CAP Investigators (Lawler PR et al.), N Engl J Med 2021;385(9):790-802, PMID 34351721. VERIFIED REMAP-CAP/ACTIV-4a/ATTACC Investigators (Goligher EC et al.), N Engl J Med 2021;385(9):777-789, PMID 34351722. VERIFIED INSPIRATION Investigators (Sadeghipour P et al.), JAMA 2021;325(16):1620-1630, PMID 33734299. VERIFIED Barnes GD et al. (Anticoagulation Forum guidance), J Thromb Thrombolysis 2020, PMID 32440883. PENDING Spyropoulos AC et al., JAMA Intern Med 2021;181(12):1612-1620, DOI 10.1001/jamainternmed.2021.6203. PENDING Lopes RD et al. (ACTION), Lancet 2021;397:2253-2263.

## Grade history (append-only)

Every grade change is kept, never overwritten, so the current grade and every prior one stay visible.

Mechanism gradeJustificationGraded byStateGraded at

ESTABLISHEDHeparin preventing and treating thrombosis is textbook pharmacology, and COVID-19's prothrombotic state (endothelial injury, immunothrombosis) was demonstrated in autopsy and cohort studies across many centers. In 2,219 non-critically ill patients, therapeutic heparin raised the probability of more organ support-free days (adjusted OR 1.27) and added 4.0 percentage points of survival to discharge without organ support, at a bleeding cost of 1.9% vs 0.9% major bleeding. HEP-COVID (257 high D-dimer patients) cut the 30-day composite of thromboembolism or death in non-ICU patients. Period guidelines recommend therapeutic heparin for non-critically ill inpatients and advise switching chronic oral anticoagulants to shorter-acting injectable agents on admission when deterioration, renal change, or procedures are a concern.admindisplayed2026-10-08T23:52:30.430Z

Outcome gradeJustificationGraded byStateGraded at

B (therapeutic dosing; stopping never tested)The large multiplatform RCT showed a real outcome signal in non-critically ill patients and HEP-COVID confirmed it in high-risk non-ICU patients, but the critically ill arm was stopped for futility and the ACTION trial contradicted the benefit, so this is not a uniformly replicated mortality win. In critically ill patients the same strategy was stopped for futility (99.9% posterior probability; survival to discharge 62.7% vs 64.5%), and INSPIRATION showed intermediate-dose escalation in the ICU was no better than standard prophylaxis (45.7% vs 44.1%) while adding severe thrombocytopenia cases. The ACTION trial showed no clinical benefit and more bleeding. The mortality signal is composite-driven, not a clean standalone death reduction. On stopping them: There is no direct human outcome evidence that discontinuation itself causes excess clots or death in this population; the claim as stated overreaches what was tested, and a discontinuation RCT does not exist to settle it.admindisplayed2026-10-08T23:52:30.430Z

[Submit evidence for or against this claim](/submit?claim=anticoagulation)

Want to hear what's next for Haygood Health?

Email me about it

Add my name and number (optional)

No spam. One email when there is something to show, and you can reply to a real person.